Optimizing the Cell Painting assay for image-based profiling.

Autor: Cimini BA; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Chandrasekaran SN; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Kost-Alimova M; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Miller L; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Goodale A; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Fritchman B; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Byrne P; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Garg S; Merck Healthcare KGaA, Darmstadt, Germany., Jamali N; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Logan DJ; Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA., Concannon JB; Chemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Lardeau CH; Janssen Pharmaceutica N.V., Beerse, Belgium., Mouchet E; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Singh S; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Shafqat Abbasi H; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Aspesi P Jr; Chemical Biology & Therapeutics Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Boyd JD; Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA., Gilbert T; Internal Medicine Research Unit, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA., Gnutt D; Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany., Hariharan S; Discovery Sciences, Pfizer, Groton, CT, USA., Hernandez D; Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hormel G; Merck Healthcare KGaA, Darmstadt, Germany., Juhani K; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Melanson M; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Mervin LH; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Monteverde T; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Pilling JE; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Skepner A; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Swalley SE; Biogen, Inc., Cambridge, MA, USA., Vrcic A; Center for Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Weisbart E; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA., Williams G; AstraZeneca BioPharmaceuticals R&D, Cambridge, UK., Yu S; Takeda Development Center Americas, Inc., San Diego, CA, USA., Zapiec B; Merck Healthcare KGaA, Darmstadt, Germany., Carpenter AE; Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA. anne@broadinstitute.org.

Publikováno v: Nature protocols [Nat Protoc] 2023 Jul; Vol. 18 (7), pp. 1981-2013. Date of Electronic Publication: 2023 Jun 21.

Bile acid analogues are activators of pyrin inflammasome.

Autor: Alimov I; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Menon S; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Cochran N; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Maher R; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Wang Q; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Alford J; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Concannon JB; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Yang Z; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Harrington E; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Llamas L; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Lindeman A; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Hoffman G; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Schuhmann T; the Novartis Institute for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland., Russ C; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Reece-Hoyes J; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and., Canham SM; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and steve.canham@novartis.com., Cai X; From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and xinming.cai@sanofi.com.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2019 Mar 08; Vol. 294 (10), pp. 3359-3366. Date of Electronic Publication: 2019 Jan 15.

Cholesterol-dependent amyloid β production: space for multifarious interactions between amyloid precursor protein, secretases, and cholesterol.

Autor: Rudajev, Vladimir¹ (AUTHOR), Novotny, Jiri¹ (AUTHOR) jiri.novotny@natur.cuni.cz

Publikováno v: Cell & Bioscience. 9/13/2023, Vol. 13 Issue 1, p1-23. 23p.

Effects of the Endocrine-Disrupting Chemicals, Vinclozolin and Polychlorinated Biphenyls, on Physiological and Sociosexual Phenotypes in F2 Generation Sprague-Dawley Rats.

Autor: Krishnan, Krittika¹, Mittal, Nitish², Thompson, Lindsay M.², Rodriguez-Santiago, Mariana³, Duvauchelle, Christine L.², Crews, David^1,4, Gore, Andrea C.^1,2,3 andrea.gore@austin.utexas.edu

Publikováno v: Environmental Health Perspectives. Sep2018, Vol. 126 Issue 9, p1-17. 17p. 1 Diagram, 4 Charts, 9 Graphs.

Peptides of Presenilin-1 Bind the Amyloid Precursor Protein Ectodomain and Offer a Novel and Specific Therapeutic Approach to Reduce ß-Amyloid in Alzheimer’s Disease.

Autor: Dewji, Nazneen N.^1,2 ndewji@ucsd.edu, Singer, S. Jonathan^2,3, Masliah, Eliezer^4,5, Rockenstein, Edward⁴, Kim, Mihyun^1,2, Harber, Martha⁶, Horwood, Taylor⁷

Publikováno v: PLoS ONE. Apr2015, Vol. 10 Issue 4, p1-22. 22p.